Core Market Access Advisors

Navigating U.S. Payer Strategies in 2025, Core Market Access Advisors is positioned as a strategic partner for pharmaceutical companies seeking to optimize market access in the complex and evolving U.S. healthcare landscape. As of March 23, 2025, the U.S. payer environment is shaped by heightened cost pressures, regulatory shifts like the Inflation Reduction Act (IRA), and an increasing demand for real-world evidence (RWE) and value-based outcomes. Our mission is to empower clients to secure timely and sustainable access to their therapies by delivering tailored, data-driven strategies that align with the priorities of U.S. payers—ranging from Medicare and Medicaid to commercial insurers and pharmacy benefit managers (PBMs)/GPOs. Current U.S. Payer Landscape, the U.S. payer ecosystem in 2025 is marked by several key trends that directly influence pharmaceutical market access: **IRA Implementation**: The IRA’s price negotiation provisions for high-cost Medicare drugs are now in full swing, with payers leveraging Maximum Fair Prices (MFPs) to tighten formulary controls. This has shifted bargaining power, requiring pharma companies to justify premiums with robust clinical and economic evidence. - **Payer Consolidation and PBM Influence**: Ongoing consolidation among payers and PBMs has amplified their ability to dictate pricing and access terms, often prioritizing cost containment over innovation unless value is demonstrated. - **Rise of Precision Medicine**: High-cost therapies like gene and cell treatments (e.g., CAR-T) are under scrutiny, pushing payers to demand innovative payment models—such as outcomes-based contracts or installment payments—to manage budget impacts. - **Evidence Expectations**: Payers increasingly require RWE, health economic outcomes research (HEOR), and patient-reported outcomes (PROs) to assess long-term value, especially as digital tools like wearables and EHRs enhance data availability. - **Formulary Pressures**: The Core Solution